$47.40
▲ +0.3% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Has CRISPR Therapeutics (CRSP) Fallen Far Enough To Look Undervalued?
Do CRISPR Therapeutics' (CRSP) EPS Projections Clarify Its Gene‑Editing Commercialisation Path?
Overview
52-week range
$37
$78
25% of range
Avg surprise (last 3)
-8.2%
Avg reaction (last 2)
-4.0%
50% positive
Latest IV / EM
59%
EM ±3.5% · $47 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $-1.28 | $-1.14 | -12.3% | +19.0% | +3.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.17 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $-1.29 | $-1.47 | +12.2% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-1.58 | $-1.27 | -24.4% | — | -11.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.01 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.49 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.43 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.98 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 3, 2026 | Jun/2026 | OTHER | -$1.10 | -$1.29 | +14.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-130M | — | $-132M | $-229M | $-148M | — | $-110M | $-151M |
| Net income | $-123M | — | $-106M | $-209M | $-136M | — | $-86M | $-126M |
| EPS (diluted) | $-1.28 | — | $-1.17 | $-2.40 | $-1.58 | — | $-1.01 | $-1.49 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B |
| Total assets | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B |
| Long-term debt | $585M | $0 | — | — | — | — | — | — |
| Total liabilities | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M |
| Total equity | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B |